A5057894542- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Lung Cancer Research Studies
- Ovarian cancer diagnosis and treatment
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Esophageal and GI Pathology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Head and Neck Cancer Studies
- Endometrial and Cervical Cancer Treatments
- Histone Deacetylase Inhibitors Research
- Health Systems, Economic Evaluations, Quality of Life
- Hormonal and reproductive studies
- Colorectal and Anal Carcinomas
- Renal cell carcinoma treatment
- Occupational and environmental lung diseases
- Prostate Cancer Treatment and Research
MRC Clinical Trials Unit at UCL
2015-2025
University College London
2016-2025
Inserm
2025
Centre de recherche en Epidémiologie et Santé des Populations
2025
Université Paris-Saclay
2025
Medical Research Council
2015-2024
Airedale General Hospital
2023
University Hospitals of Leicester NHS Trust
2023
Queen's University Belfast
2019
University of Amsterdam
2019
BackgroundWhole brain radiotherapy (WBRT) and dexamethasone are widely used to treat metastases from non-small cell lung cancer (NSCLC), although there have been no randomised clinical trials showing that WBRT improves either quality of life or overall survival. Even after treatment with WBRT, the prognosis this patient group is poor. We aimed establish whether could be omitted without a significant effect on survival life.MethodsThe Quality Life Treatment for Brain Metastases (QUARTZ) study...
Mismatch repair (MMR) deficiency (MMRD) and microsatellite instability (MSI) are prognostic for survival in many cancers resistance to fluoropyrimidines early colon cancer. However, the effect of MMRD MSI curatively resected gastric cancer treated with perioperative chemotherapy is unknown.
Purpose The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial established perioperative epirubicin, cisplatin, and fluorouracil chemotherapy as a standard of care for patients with resectable esophagogastric cancer. However, identification at risk relapse remains challenging. We evaluated whether pathologic response lymph node status after neoadjuvant are prognostic in treated the MAGIC trial. Materials Methods Pathologic regression was assessed resection...
The diagnosis and staging of lung cancer is an important process that identifies treatment options guides disease prognosis. We aimed to assess endobronchial ultrasound-guided transbronchial needle aspiration as initial investigation technique for patients with suspected cancer.In this open-label, multicentre, pragmatic, randomised controlled trial, we recruited who had undergone a CT scan stage I IIIA cancer, from six UK centres randomly assigned them either (EBUS-TBNA) or conventional...
The current management of advanced non-small cell lung cancer (NSCLC) requires differentiation between squamous and nonsquamous subtypes as well epidermal growth factor receptor (EGFR) mutation status. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is increasingly used for the diagnosis staging cancer. However, it unclear whether cytology specimens obtained with EBUS-TBNA are suitable subclassification genotyping NSCLC.To determine from in routine practice...
BackgroundNeoadjuvant chemotherapy before surgery improves survival compared with alone for patients oesophageal cancer. The OE05 trial assessed whether increasing the duration and intensity of neoadjuvant further improved current standard regimen.MethodsOE05 was an open-label, phase 3, randomised clinical trial. Patients surgically resectable adenocarcinoma classified as stage cT1N1, cT2N1, cT3N0/N1, or cT4N0/N1 were recruited from 72 UK hospitals. Eligibility criteria included WHO...
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has emerged as an important tool for the diagnosis and staging of lung cancer but its role in tuberculous intrathoracic lymphadenopathy not been established. The aim this study was to describe diagnostic utility EBUS-TBNA patients with due tuberculosis (TB).
BackgroundResponse to immunotherapy in gastric cancer is associated with microsatellite instability (or mismatch repair deficiency) and Epstein-Barr virus (EBV) positivity. We therefore aimed develop validate deep learning-based classifiers detect EBV status from routine histology slides.MethodsIn this retrospective, multicentre study, we collected tissue samples ten cohorts of patients seven countries (South Korea, Switzerland, Japan, Italy, Germany, the UK USA). trained a classifier...
5500 Background: First line treatment of advanced ovarian cancer (OC) is accepted to be primary surgery (PS) followed by adjuvant platinum-based chemotherapy (P-CT). However, the EORTC55971 trial suggested neoadjuvant (NACT) an alternative, showing increased optimal debulking rates and reduced surgical complications without detriment survival. CHORUS (CRUK 07/009) 2nd phase III randomized controlled investigate timing initial in OC. Methods: Patients (pts) with clinical FIGO stage III-IV OC...
4002 Background: Neoadjuvant chemotherapy (2 cycles cisplatin/5 fluorouracil) (CF) followed by surgery is a standard of care for locally advanced oesophageal cancer. We investigated whether more (4 epirubicin/cisplatin /capecitabine (ECX)) would improve outcomes. Methods: A multi-centre, randomised, phase III trial comparing 2 CF with 4 ECX oesophagectomy 2-field lymphadenectomy lower and junctional (Types I II) adenocarcinoma. Primary outcome was overall survival (OS); 842 patients (677...
PURPOSE The optimal neoadjuvant treatment for resectable carcinoma of the thoracic esophagus (TE) or gastroesophageal junction (GEJ) remains a matter debate. We performed an individual participant data (IPD) network meta-analysis (NMA) randomized controlled trials (RCTs) to study effect chemotherapy chemoradiotherapy, with focus on tumor location and histology subgroups. PATIENTS AND METHODS All, published unpublished, RCTs closed accrual before December 31, 2015 having compared at least two...
BackgroundOesophageal (OeC) and gastric (GC) cancer patients are treated with similar multimodal therapy have poor survival. There remains an urgent clinical need to identify biomarkers individualise patient management improve outcomes. Therapy immune checkpoint inhibitors has shown promising results in other cancers. Proposed predict potential response include DNA mismatch repair (MMR) and/or Epstein–Barr virus (EBV) status. The aim of this study was establish compare EBV status MMR large...
Objectives To compare quality‐of‐life (QoL) outcomes at 6 months between men with advanced prostate cancer receiving either transdermal oestradiol ( tE 2) or luteinising hormone‐releasing hormone agonists LHRH a) for androgen‐deprivation therapy ADT ). Patients and methods Men locally metastatic participating in an ongoing randomised, multicentre UK trial comparing 2 versus a were enrolled into QoL sub‐study. was delivered via three four transcutaneous patches containing 100 μg/24 h....